Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Injectable cabotegravir and rilpivirine are approved for people with viral suppression who would prefer monthly injections to daily pills.
The European Medicines Agency gave the green light to injectable cabotegravir and rilpivirine for HIV treatment.
The FDA recently held up the U.S. approval based on concerns over the monthly injectable regimen’s manufacturing.
This finding could potentially offer a way to blunt Zika’s devastating impact.
A major plus of the implant is that it can be easily removed if necessary.
The experimental long-acting injectable regimen of cabotegravir and rilpivirine stands poised for approval.
Given every four weeks, the combo injection of cabotegravir and Edurant (rilpivirine) will likely face an FDA decision by early 2020.
The trial will investigate whether injections of long-acting cabotegravir and rilpivirine yield a superior rate of viral suppression.
Dosed every four weeks, the injection, which requires a clinic visit, includes long-acting rilpivirine and cabotegravir.
The Conference on Retroviruses and Opportunistic Infections in Seattle saw many important studies that are advancing the fight against HIV.
Participants in a study were started on daily oral drugs and then half were switched over to long-acting meds.
Given every four weeks, combo injections of cabotegravir and rilpivirine will likely face an FDA decision by early 2020.
Promising findings from a study of a two-drug injectable treatment given every four weeks.
The company has released new data from a trial of injectable cabotegravir and Edurant given every four or eight weeks.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.